Drugs / NKG2D CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04717999 | Sep 2021 → Sep 2023 | glioblastoma | UWELL Biopharma | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04717999 ↗ |
| Modality | Cell therapy | “This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma” NCT04717999 ↗ |
| Route | Other | “The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter.” NCT04717999 ↗ |